MedPath

A clinical observation to study the safety of Sidhha medicine- Arumuga Chenduram.

Phase 2
Conditions
Health Condition 1: M199- Osteoarthritis, unspecified site
Registration Number
CTRI/2020/08/026988
Lead Sponsor
Ayothidoss pandithar hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Patients who taking herbo mineral drug arumuga chenduram for 48 days

Exclusion Criteria

PREGNANCY

Lactation

Patients with renal and liver disease

Patients with cardiovascular disease

Patients with gastric or peptic ulcer and GERD

Patients with frequent flatulence and indigestion

History of major systemic illness

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To assess any changes in blood parameters and clinical symptoms during treatment, <br/ ><br>To analysis presence of mercury and iron level in bloodTimepoint: 6months
Secondary Outcome Measures
NameTimeMethod
Toassess any changes in blood parameters and clinical symptoms during treatment <br/ ><br>To analysis iron and mercury level in bloodTimepoint: 6 months
© Copyright 2025. All Rights Reserved by MedPath